<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415555</url>
  </required_header>
  <id_info>
    <org_study_id>KE-0254/26/2018</org_study_id>
    <nct_id>NCT03415555</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesia After Minithoracotomy</brief_title>
  <official_title>Efficacy of Erector Spinae Plane (ESP) Blockade in Patients Scheduled for Minimally Invasively Mitral Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Rzeszów</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients scheduled for minimally invasive mitral valve replacement. Each patient will be
      treated with intravenous (i.v.) oxycodone - patient-controlled analgesia (PCA). Half of the
      patients will be randomly allocated to Erector Spinae Plane (ESP) blockade group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only patients who are qualified for an elective procedure of mitral valve replacement may
      participate in the study. Each patient will be anesthetized generally. The same drugs will be
      used in each stage of anesthesia. The induction: etomidate, remifentanil, rocuronium, scolina
      as required. The maintenance: sevoflurane, remifentanil, rocuronium. The emergence: oxygen,
      sugammadex or neostigmine a required.

      Patients will be randomly allocated into one of two groups: PCA or ESP. Among the patients
      from ESP group will have ESP blockade before the induction of general anesthesia. ESP
      blockade will be performed under ultrasound control. A single-shot technique will be used
      with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.

      Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA
      with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
      This is standard protocol in our department.

      Only patients who are successfully awakened after the procedure may participate in the study.

      The pain intensity will be assessed with visual-analogue scale (VAS) at 2, 4, 8, 12 and 24
      hour after the end of anesthesia.

      The total consumption of oxycodone will be also monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">June 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single (Participant)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>From the end of anesthesia till 24 hour postoperatively. VAS range from 0 (no pain, good outcome) to 100 in millimeters (the worst pain ever, bad outcome).</time_frame>
    <description>Patients' self-pain assessment with VAS (visual-analogue scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of oxycodone</measure>
    <time_frame>From the end of anesthesia till 24 hour postoperatively</time_frame>
    <description>The cumulative consumption of oxycodone during 24 hour from the end of anesthesia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Mitral Valve Disease</condition>
  <arm_group>
    <arm_group_label>ESP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector Spinae Plane blockade</intervention_name>
    <description>Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.</description>
    <arm_group_label>ESP</arm_group_label>
    <other_name>ESP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.</description>
    <arm_group_label>ESP</arm_group_label>
    <arm_group_label>PCA</arm_group_label>
    <other_name>PCA with oxycodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>general anesthesia</intervention_name>
    <description>Each patient will generally anesthetized and endotracheal tube will be inserted</description>
    <arm_group_label>ESP</arm_group_label>
    <arm_group_label>PCA</arm_group_label>
    <other_name>GA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>Paracetamol will be given i.v. every 6 hours.</description>
    <arm_group_label>ESP</arm_group_label>
    <arm_group_label>PCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled mitral valve replacement surgery

          -  obtained consent

        Exclusion Criteria:

          -  allergy to oxycodone and local anesthetics

          -  depression, antidepressant drugs treatment

          -  epilepsy

          -  usage of painkiller before surgery

          -  addiction to alcohol or recreational drugs

          -  postoperative ventilation or ICU admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirosław Czuczwar, M.D., PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Lublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michał Borys, M.D., PhD</last_name>
    <phone>506350569</phone>
    <email>michalborys1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Jadwiga Hospital</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Horeczy, M.D.</last_name>
      <phone>+48 784445414</phone>
      <email>beata.horeczy@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Michał Borys</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Erector Spinae Plane blockade</keyword>
  <keyword>patient control anlagesia</keyword>
  <keyword>mitral valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

